A kaleidoscope represents ever-changing phases and events and with a few turns of the kaleidoscope, a beautiful new pattern emerges. For us, having a kaleidoscope on the cover represents positive change and growth, where we reimagine our business and a new symmetry is revealed.

Know more
Financial highlights

`19,427 mn

REVENUE

`3,454 mn

EBITDA

`1,605 mn

PAT

~73%

EXPORT REVENUE

17.8%

EBITDA MARGIN

8.3%

PAT MARGIN

15.2%

ROCE

`13.0

EPS
Non-financial highlights

Environment

29%

RENEWABLE ENERGY USED
Social

200,000+

BENEFICIARIES
Governance

50%

OF INDEPENDENT DIRECTORS
Soaring Higher
Against
Headwinds

Future Outlook

We aspire to be a sustainable company driven by technology, execution focused while remaining customer-oriented, delivering best-in-class service across all verticals. We are well positioned to capitalise on the significant opportunities in the current global shift of supply chain to India. I am confident we will scale to new heights in the upcoming year and future.

Jai Hiremath
Executive Chairman


Poised for
Growth

Incorporated in 1988, Hikal Limited has emerged as one of the preferred partners for global companies in segments such as pharmaceuticals, crop protection, animal health, biocides, and specialty chemicals.

Know more

Project Pinnacle

In pursuit of our commitment towards transforming into a greater and fast-growing organisation, last year, we launched ‘Project Pinnacle.’ The aim is to bolster strategic pillars, and enter the next phase of growth to achieve our vision.

34+

YEARS

2,850

EMPLOYEES

`49,000 mn1

MARKET CAP

`10,680 mn

NET WORTH

1 AS OF 31 March 2022

Our presence
Locally Rooted,
Globally Spread

We have five manufacturing facilities across three states in India. We supply our products to customers across the globe in the US, Japan, Europe, Canada, South East Asia, LATAM, India and RoW.

Know more

USA

Europe


India

Japan

Manufacturing
Facilities
Know more
Jigani Unit 1, Karnataka
  • US FDA Approved API and Advanced Intermediates Manufacturing Site
  • cGMP Multipurpose API Facilities

626 M3

TOTAL REACTOR VOLUME

905

HUMAN CAPITAL
Jigani Unit 2, Karnataka
  • Scale-up and Launch Plant
  • Multipurpose and Multiproduct cGMP Facility – APIs and Intermediates

93 M3

TOTAL REACTOR VOLUME

155

HUMAN CAPITAL
Panoli, Gujarat
  • US FDA Approved Site for KSMs and AIs
  • Three Multi-purpose Manufacturing Facilities

693 M3

TOTAL REACTOR VOLUME

565

HUMAN CAPITAL
Mahad, Maharashtra
  • First Manufacturing Facility of Hikal
  • Specialty Chemicals, Fungicides, Herbicides, and Intermediate Manufacturing Site

531 M3

TOTAL REACTOR VOLUME

296

HUMAN CAPITAL
Taloja, Maharashtra
  • Commissioned in 1997 in Technical Collaboration with Merck
  • Fungicides, Insecticides, and Intermediates Manufacturing Site

600 M3

TOTAL REACTOR VOLUME

368

HUMAN CAPITAL
Panoli, Gujarat
  • Acquired Manufacturing site from Novartis in 2000
  • Specialty Chemicals, Insecticides, and Intermediates Manufacturing Site

765 M3

TOTAL REACTOR VOLUME

94

HUMAN CAPITAL
Key
Regulatory
Approvals
Business Overview
Marching Ahead
with Strategy

Under the two established growth engines of pharmaceutical and crop protection as well as the emerging animal health business, Hikal offers a diversified portfolio of products and services.

Our Primary Business Segments

Pharmaceuticals

Crop Protection

Know more
Pharmaceuticals

We specialise in manufacturing APIs and intermediates in our pharmaceutical division. Within our pharmaceutical division, we offer human health and animal health products.

Hikal is a partner of choice in

Human Health

Animal Health

Know more
Crop Protection

We offer the best-in-class products for crop protection companies, using our manufacturing excellence and technical expertise. The primary product offerings include insecticides, fungicides, herbicides, biocides, and intermediates.

Crop Protection Division – Value Enablers

30+ Years
of Experience

Strong Product
Pipeline

Multi-use
Asset Base

Know more
KEY PERFORMANCE INDICATORS
Sustained Performance
Against Odds

Revenue

19,427 mn

EBITDA

3,454 mn

PAT

1,605 mn

Net Worth

10,680 mn

EPS

13.02

DPS

₹1.6
Being
Adaptive
and
Proactive
Know more
Driving Growth
Across
Businesses
Human Health

Our business environment is ripe with opportunity. The human health industry, especially in the CDMO segment, is expected to be on a high growth trajectory.

The growing need for outsourcing by global pharmaceutical companies and our competitive advantage make our human health vertical well poised to be a growth engine for our Company.

Animal Health

The animal health industry is full of untapped potential, with less competition, and is expected to grow in the future.

The business environment makes expansion into animal health lucrative for us and our animal health vertical is expected to grow multi-fold in the near future.

Crop Protection

The crop protection industry is set to make recovery and bounce back.

Our product pipeline, along with a positive business environment, is expected to make our crop protection vertical a strong driver of our growth in the near future.

Value Creation Model
Expanding Capacity,
Augmenting Growth
Inputs
Our Value Creation Process
Creating Value for Stakeholders
Outputs
Financial Capital

0.59

NET DEBT-EQUITY RATIO

`10,680 million

NET WORTH
Manufactured Capital

5

PRODUCTION PLANTS

4,100 M3

CAPACITY
Intellectual Capital

336

PERSONNEL IN R&T AND TECHNICAL SERVICES
Human Capital

2,850

EMPLOYEES
Social and Relationship Capital

`31.6 million

CSR EXPENDITURE
Natural Capital

7,03,40,409 KWH

ENERGY CONSUMPTION

10,99,478 KL

WATER CONSUMPTION
Our Growth Drivers

Pharmaceuticals

Animal Health

Food Ingredients

Crop Protection

Biocides

Specialty Chemicals

Research & Technology

Customers

Employees

Investors and
Shareholders

Community

Institutions and
Industry Bodies

Suppliers

Government and
Regulators

Media and
Analysts


Financial Capital

`19,427 million

REVENUE

15.2%

ROCE

`3,454 million

EBITDA

180%

MARKET CAP

2.5x

SHARE PRICE INCREASE IN 2021-22

(Increase in March 2021 to March 2022)

Manufactured Capital

~6,500 MT

MT ACTIVE INGREDIENTS SOLD IN 2021-22

~1,200 MT

MT ADVANCED INTERMEDIATES SOLD IN 2021-22
Intellectual Capital

1

MINI PLANT (SCALE UP & PILOT)

1

RESEARCH & TECHNOLOGY CENTRE
Human Capital

0

LOST TIME INJURY

(Per Million Hours)

6%

WOMEN IN WORKFORCE

10,166

TOTAL TRAINING HOURS RECEIVED
Social and Relationship Capital

200,000+

CSR BENEFICIARIES
Natural Capital

8% (84,734 KL)

WATER RECYCLED

29% (2,05,52,814 KWH)

RENEWABLE ENERGY USED
Strategic Pillars
Capitalising on
Strengths

Know more

We, at Hikal, have charted strategic pillars, which take advantage of our growth engines, to enable value creation and achieve our growth targets. These strategic pillars are based upon maintaining our competitive advantage in the market, and expanding them.

Our Strategic Pillars
SP1: ESG

Our pillar of ESG relies upon increasing our natural capital, social and relationship capital in an efficient governance structure. This leads to alignment of our well-being with the collective good.

SP2: Compliance

We, at Hikal, understand the importance of regulations and strive to ensure we do business safely and responsibly. Our compliance relies on our commitment to green chemistry and green engineering.

SP3: Customer Centricity

Our business strategy relies on creating a unique value proposition for our customers. We strive to provide cost-effective quality products, manufacture them with excellence using our technical capabilities, improve our downstream supply considerations, and ensure we satisfy the highest ethical standards.

SP4: Research and Technology

Our aim is to harness science and technology to create world-class, sustainable products and solutions for customers, and enhance productivity of our sites and profitability of our businesses.

SP5: Manufacturing Excellence

Our pillar of manufacturing excellence relies on capacity, capability, and compliance. We remain committed to an expansion of capacity through self-funding. This year, we undertook several initiatives to ensure our existing and future capacities are used as efficiently as possible.

SP6: Supply Chain Management

As evident from the disruptions that stemmed from the recent past, supply chain risk is substantial and a threat to profitability. Our strategic pillar of supply chain management relies on backward integrating, finding alternative sources and partnerships, localisation, and digitisation. During the year, we undertook some efforts to de-risk our business from supply chain shocks.

ESG - Our approach towards sustainability
Being Responsible
for Tomorrow

We believe that sustainability is key to our long-term success, and to create value for our stakeholders. Embedding ESG into our operations enables us to create a positive impact on the environment, our people, and the communities we operate in.

Energy Efficiency

Responsible use of natural resources and usage of renewable energy

Emission Management

Reducing our emissions and contributing to combatting climate change

Water Management

Water conservation, restoration of water bodies

Waste Optimisation

Safe disposal, recycling, waste recovery and reduction of waste generation at the source

Biodiversity

Preservation of biodiversity to ensure natural capital is enhanced

Employee Safety

Safety of work environment for employees across value chains

Employee Engagement & Diversity

Practices, policies, and culture supporting diversity, equity, and inclusion

Fair Sourcing

Fair practices for suppliers throughout the supply chain

Community Relations

Equitable interactions with communities

Transparency and Risk Management

Responsible disclosure and management of risks

Quality Governance

Practices related to good governance and ethics

Corporate Governance

Governance framework and regulatory compliance

Know more
Awards and Recognition

Golden Peacock Award for Corporate Social Responsibility

Great Place to Work®

66 Rank

India’s Top 100 Best Companies to Work for in 2021

Download Center